

Statement of Advice:

tafamidis meglumine (Vyndaqel®) 20mg soft capsules (No: 877/13) **Pfizer Limited**

05 April 2013

ADVICE: in the absence of a submission from the holder of the marketing authorisation

tafamidis meglumine (Vyndaqel®) is not recommended for use within NHS Scotland.

Indication under review: treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment,

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

**Chairman,
Scottish Medicines Consortium**